{
  "docId": "019dd923-622b-71dc-a6dd-1b2358468037",
  "docSlug": "b6b6f532847a",
  "documentTitle": "Samsung C&T Corporation (028260 KS)",
  "authorId": "24_Palliser_Capital",
  "authorName": "Palliser",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-12-06 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 23,
  "pageCount": 60,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "valuation_reveal",
  "function": "quantify_opportunity",
  "density": "overcrowded",
  "nDataPoints": 35,
  "notes": "Includes a valuation bridge/discount visualization and a peer comparison chart.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "callout_box",
    "line_chart",
    "bar_chart_vertical",
    "bar_chart_grouped",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6dd-1b2358468037/23",
  "deckHref": "/decks/019dd923-622b-71dc-a6dd-1b2358468037",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6dd-1b2358468037.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6dd-1b2358468037#slide-23",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Samsung Biologics is a top tier global CDMO company, and SCT's deep trading discount provides an attractive entry valuation to own this premium stock",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8ca-a94693cb0144",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.45,
        "x": 0.51,
        "y": 0.68
      },
      "kind": "chart",
      "text": "Trading Peers EV / EBITDA 24E",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "468958b9-3a6c-4a1e-aa65-0839ae554f14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.63
      },
      "kind": "chart",
      "text": "Revenue ($m) and EBITDA ($m) projections",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64e66949-5236-46ad-a2f1-738fb6caf1e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.51,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Share Price Performance Since IPO (post-Cheil Merger) (KRW)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c410568-92ae-4672-b963-a9b33bbfb260",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.45,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "World-leading CDMO service provider and biosimilars developer partnering with global biopharma companies; Market cap KRW51tn ($39bn); Four plants with 604KL total capacity for CDMO + a 5th by 2025; Contracts of long duration with 14 big pharma clients; Samsung Biologics was founded in 2011 and spun-out of SCT in 2016",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a7abaf3-e845-492b-8527-f4a609fdcae9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "EV / EBITDA 24E: 10.3x",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-25b7-709e-b8ca-afe3097bccfe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Samsung Biologics is a top tier global CDMO company, and SCT's deep trading discount provides an attractive entry valuation to own this premium stock",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd692112-e928-4684-baf9-ecbfda8287ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Company, Bloomberg, Analyst research; Market data as of 1 Dec 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "339dbd32-59c3-4632-821d-bd406ee7b931",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "SCT's Shares Offer an Opportunity to Indirectly Invest In Two World-Leading Companies at Levels not Seen for Years – (2) Samsung Biologics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f6e259e-474b-4b58-a067-66a7acaa91fb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "valuation-bridge",
      "slug": null,
      "matchId": "ebf2a293-b726-4d1f-b01a-079219328def",
      "evidence": "Visual representation of share price entry point discount",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 35,
      "from": 16,
      "beatId": "5bcde41d-6d43-4054-83fd-7947f9d155c2",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem by highlighting the causes of the value gap, including inefficient capital allocation and governance issues.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 18,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "9dd92b8f-477e-45af-a756-f15c5ca90d4d",
      "evidence": "The document provides a detailed breakdown of SCT's intrinsic value, highlighting its various business segments and their contributions to its overall value.",
      "position": 1,
      "objective": "How can SCT's intrinsic value be broken down?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}